Compare Biogen Inc (BIIB) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kraft Heinz Co — how do they compare? Biogen Inc trades at $207.69 (market cap $30.13B), while Kraft Heinz Co trades at $24.44 (market cap $29.23B). The key difference: Biogen Inc and Kraft Heinz Co are close in size by market cap, and Kraft Heinz Co pays a 6.49% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KHC | |
|---|---|---|
Market Cap | $30.13B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $28.06 |
52-Week Low | $128.93 | $21.21 |
Enterprise Value | $37.20B | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Kraft Heinz (KHC) trades at $24.36, down 2.29% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates, but net income margin is negative at -13.64%. The company maintains a $0.40 quarterly dividend, while analyst consensus is mostly Hold. Cash flow from operations improved to $4.46B in 2025, though revenue declined to $24.94B.
Outlook remains cautious due to profit declines and competitive pressures, offset by a low P/E of 13.04 and strategic investments. Key risks include earnings sustainability and high debt. The stock presents value potential but requires monitoring of turnaround execution under CEO Cahillane's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
